A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.

NCT07836140 on ClinicalTrials.gov · last registry update 2026-09-23

Finished 25 April 2025, after enrolling 60 people. Primary outcome, as filed: HOMA2-β index. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Second Affiliated Hospital of Soochow University
Sponsor type: Other
Enrollment: 60
Started: 2024-04-22
Primary completion: 2025-04-25 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-09-23	First seen in registry	Registered as COMPLETED, P2

Primary outcome

HOMA2-β index

Conditions studied

Obesity / Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.